|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for DAPK2 |
 Gene summary |
| Basic gene Info. | Gene symbol | DAPK2 |
| Gene name | death-associated protein kinase 2 | |
| Synonyms | DRP-1|DRP1 | |
| Cytomap | UCSC genome browser: 15q22.31 | |
| Type of gene | protein-coding | |
| RefGenes | NM_014326.3, | |
| Description | DAP kinase 2DAP-kinase-related protein 1 beta isoform | |
| Modification date | 20141207 | |
| dbXrefs | HGNC : HGNC | |
| Ensembl : ENSG00000035664 | ||
| HPRD : 09905 | ||
| Vega : OTTHUMG00000132947 | ||
| Protein | UniProt: Q9UIK4 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_DAPK2 | |
| BioGPS: 23604 | ||
| Pathway | NCI Pathway Interaction Database: DAPK2 | |
| KEGG: DAPK2 | ||
| REACTOME: DAPK2 | ||
| Pathway Commons: DAPK2 | ||
| Context | iHOP: DAPK2 | |
| ligand binding site mutation search in PubMed: DAPK2 | ||
| UCL Cancer Institute: DAPK2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006468 | protein phosphorylation | 10376525 | GO:0035556 | intracellular signal transduction | 10376525 |
| Top |
| Ligand binding site mutations for DAPK2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | S31 | S31I | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for DAPK2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | S31 | S31I | -0.25727607 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for DAPK2 from PDB |
| Top |
| Differential gene expression and gene-gene network for DAPK2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for DAPK2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for DAPK2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of DAPK2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of DAPK2 |
| Multiple alignments for Q9UIK4 in multiple species |
| LBS | AA sequence | # species | Species | A50 | TGLEYAAKFIK | 2 | Homo sapiens, Mus musculus | A50 | NGTEFACKTLK | 1 | Arabidopsis thaliana | E104 | VVLILELVSGG | 2 | Homo sapiens, Mus musculus | E104 | FHLVMELCSGG | 1 | Arabidopsis thaliana | G30 | IGEELGSGQFA | 2 | Homo sapiens, Mus musculus | G30 | FGRNIGKGKFG | 1 | Arabidopsis thaliana | I170 | PHIKLIDFGLA | 2 | Homo sapiens, Mus musculus | I170 | -KIQLADFGLA | 1 | Arabidopsis thaliana | I87 | -HHNVITLHDV | 1 | Homo sapiens | I87 | GHPRVVTLHAV | 1 | Arabidopsis thaliana | I87 | -HPNIITLHDV | 1 | Mus musculus | L105 | VLILELVSGGE | 2 | Homo sapiens, Mus musculus | L105 | HLVMELCSGGR | 1 | Arabidopsis thaliana | L29 | DIGEELGSGQF | 2 | Homo sapiens, Mus musculus | L29 | VFGRNIGKGKF | 1 | Arabidopsis thaliana | M156 | KPENIMLLDKN | 2 | Homo sapiens, Mus musculus | M156 | KPENILLTAAG | 1 | Arabidopsis thaliana | S31 | GEELGSGQFAI | 2 | Homo sapiens, Mus musculus | S31 | GRNIGKGKFGS | 1 | Arabidopsis thaliana | V106 | LILELVSGGEL | 2 | Homo sapiens, Mus musculus | V106 | LVMELCSGGRL | 1 | Arabidopsis thaliana | V37 | GQFAIVKKCRE | 2 | Homo sapiens, Mus musculus | V37 | GKFGSVRICKS | 1 | Arabidopsis thaliana |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |